8-K filing — CorMedix Inc. (CRMD)
Filed: 2026-11-16 AccNo: 0001213900-26-120016 Size: 350 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Filings · News reference
A CorMedix insider recently acquired company shares valued at approximately $390,000, as disclosed in a recent SEC filing.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-11-16 AccNo: 0001213900-26-120016 Size: 350 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Following the company's third-quarter earnings report, analysts from Oppenheimer and RBC adjusted their price targets for CorMedix while maintaining positive ratings.
Major M&A deals this week include: CorMedix buys Heron for $145M and Craveworthy Brands buys New England Authentic Eats.
Cormedix (NASDAQ:CRMD) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. For
CorMedix announced its financial results for the third quarter ended September 30, 2026, reporting $54.5 million in consolidated revenue and a net loss of $14.7 million.